Array-818-202 for Non-small Cell Lung Cancer - Clinical Trial

What is the Purpose of this Study?

If you choose to join this study, you will:
-Be in the study up to 2 years
-Take study drugs daily
-Give blood samples
-Possible give a small lung tissue sample
-Continue with your regular care

What is the Condition Being Studied?

Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults 19 years or older with NSCLC with a gene called BRAFV600E that has mutated.

Age Group

What is Involved?

We are doing this study to learn about the safety and effectiveness of the study drugs (Encorafenib and Binimetinib) in patients.

Study Details

Full Title
PHAROS: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF-V600 mutant Non-small Cell Lung Cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00102193
NCT: NCT03915951
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center